Human fused NKG2D–IL-15 protein controls xenografted human gastric cancer through the recruitment and activation of NK cells (original) (raw)

• Steel JC, Waldmann TA, Morris JC . Interleukin-15 biology and its therapeutic implications in cancer. Trends Pharmacol Sci 2012; 33: 35–41.
  Article CAS Google Scholar
• Jakobisiak M, Golab J, Lasek W . Interleukin 15 as a promising candidate for tumor immunotherapy. Cytokine Growth Factor Rev 2011; 22: 99–108.
  Article CAS Google Scholar
• Sanjabi S, Mosaheb MM, Flavell RA . Opposing effects of TGF-beta and IL-15 cytokines control the number of short-lived effector CD8+ T cells. Immunity 2009; 31: 131–144.
  Article CAS Google Scholar
• Tao Q, Chen T, Tao L, Wang H, Pan Y, Xiong S et al. IL-15 improves the cytotoxicity of cytokine-induced killer cells against leukemia cells by upregulating CD3+CD56+ cells and downregulating regulatory T cells as well as IL-35. J Immunother 2013; 36: 462–467.
  Article CAS Google Scholar
• Berger C, Berger M, Hackman RC, Gough M, Elliott C, Jensen MC et al. Safety and immunologic effects of IL-15 administration in nonhuman primates. Blood 2009; 114: 2417–2426.
  Article CAS Google Scholar
• Imamura M, Shook D, Kamiya T, Shimasaki N, Chai SM, Coustan-Smith E et al. Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15. Blood 2014; 124: 1081–1088.
  Article CAS Google Scholar
• Yiang GT, Chou RH, Chang WJ, Wei CW, Yu YL . Long-term expression of rAAV2-hIL15 enhances immunoglobulin production and lymphokine-activated killer cell-mediated human glioblastoma cell death. Mol Clin Oncol 2013; 1: 321–325.
  Article Google Scholar
• Zhao DX, Li ZJ, Zhang Y, Zhang XN, Zhao KC, Li YG et al. Enhanced antitumor immunity is elicited by adenovirus-mediated gene transfer of CCL21 and IL-15 in murine colon carcinomas. Cell Immunol 2014; 289: 155–161.
  Article CAS Google Scholar
• Bessard A, Solé V, Bouchaud G, Quéméner A, Jacques Y . High antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor alpha fusion protein, in metastatic melanoma and colorectal cancer. Mol Cancer Ther 2009; 8: 2736–2745.
  Article CAS Google Scholar
• Kermer V, Baum V, Hornig N, Kontermann RE, Müller D . An antibody fusion protein for cancer immunotherapy mimicking IL-15 trans-presentation at the tumor site. Mol Cancer Ther 2012; 11: 1279–1288.
  Article CAS Google Scholar
• Cheever MA . Twelve immunotherapy drugs that could cure cancers. Immunol Rev 2008; 222: 357–368.
  Article CAS Google Scholar
• Müller JR, Waldmann TA, Kruhlak MJ, Dubois S . Paracrine and trans-presentation functions of IL-15 are mediated by diverse splice versions of IL-15Rα in human monocytes and dendritic cells. J Biol Chem 2012; 287: 40328–40338.
  Article Google Scholar
• Lucas M, Schachterle W, Oberle K, Aichele P, Diefenbach A . Dendritic cells prime natural killer cells by trans-presenting interleukin 15. Immunity 2007; 26: 503–517.
  Article CAS Google Scholar
• Castillo EF, Schluns KS . Regulating the immune system via IL-15 trans-presentation. Cytokine 2012; 59: 479–490.
  Article CAS Google Scholar
• Huntington ND, Alves NL, Legrand N, Lim A, Strick-Marchand H, Mention JJ et al. IL-15 trans-presentation promotes both human T-cell reconstitution and T-cell-dependent antibody responses in vivo. Proc Natl Acad Sci USA 2011; 108: 6217–6222.
  Article CAS Google Scholar
• Kobayashi H, Dubois S, Sato N, Sabzevari H, Sakai Y, Waldmann TA et al. Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance. Blood 2005; 105: 721–727.
  Article CAS Google Scholar
• Stoklasek TA, Schluns KS, Lefrançois L . Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo. J Immunol 2006; 177: 6072–6080.
  Article CAS Google Scholar
• Dubois S, Patel HJ, Zhang M, Waldmann TA, Müller JR . Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor action. J Immunol 2008; 180: 2099–2106.
  Article CAS Google Scholar
• Waldmann TA, Conlon KC, Stewart DM, Worthy TA, Janik JE, Fleisher TA et al. Phase 1 trial of IL-15 trans presentation blockade using humanized Mikβ1 mAb in patients with T-cell large granular lymphocytic leukemia. Blood 2013; 121: 476–484.
  Article CAS Google Scholar
• Bouchaud G, Garrigue-Antar L, Solé V, Quéméner A, Boublik Y, Mortier E et al. The exon-3-encoded domain of IL-15R alpha contributes to IL-15 high-affinity binding and is crucial for the IL-15 antagonistic effect of soluble IL-15Ralpha. J Mol Biol 2008; 382: 1–12.
  Article CAS Google Scholar
• Ullrich E, Koch J, Cerwenka A, Steinle A . New prospects on the NKG2D/NKG2DL system for oncology. Oncoimmunology 2013; 2: e26097 .
  Article Google Scholar
• Wu J, Song Y, Bakker AB, Bauer S, Spies T, Lanier LL et al. An activating immunoreceptor complex formed by NKG2D and DAP10. Science 1999; 285: 730–732.
  Article CAS Google Scholar
• Hayakawa Y . Targeting NKG2D in tumor surveillance. Expert Opin Ther Targets 2012; 16: 587–599.
  Article CAS Google Scholar
• Salih HR, Holdenrieder S, Steinle A . Soluble NKG2D ligands: prevalence, release, and functional impact. Front Biosci 2008; 13: 3448–3456.
  Article CAS Google Scholar
• Zhang T, Sentman CL . Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells. Cancer Res 2011; 71: 2066–2076.
  Article CAS Google Scholar
• Xia Y, Chen B, Shao X, Xiao W, Qian L, Ding Y et al. Treatment with a fusion protein of the extracellular domains of NKG2D to IL-15 retards colon cancer growth in mice. J Immunother 2014; 37: 257–266.
  Article CAS Google Scholar
• Gong W, Xiao W, Hu M, Weng X, Qian L, Pan X et al. Ex vivo expansion of natural killer cells with high cytotoxicity by K562 cells modified to co-express major histocompatibility complex class I chain-related protein A, 4-1BB ligand, and interleukin-15. Tissue Antigens 2010; 76: 467–475.
  Article CAS Google Scholar
• Lin Z, Wang C, Xia H, Liu W, Xiao W, Qian L et al. CD4(+) NKG2D(+) T cells induce NKG2D down-regulation in natural killer cells in CD86-RAE-1ε transgenic mice. Immunology 2014; 141: 401–415.
  Article CAS Google Scholar
• Mrózek E, Anderson P, Caligiuri MA . Role of interleukin-15 in the development of human CD56+ natural killer cells from CD34+ hematopoietic progenitor cells. Blood 1996; 87: 2632–2640.
  PubMed Google Scholar
• Barao I, Alvarez M, Redelman D, Weiss JM, Ortaldo JR, Wiltrout RH et al. Hydrodynamic delivery of human IL-15 cDNA increases murine natural killer cell recovery after syngeneic bone marrow transplantation. Biol Blood Marrow Transplant 2011; 17: 1754–1764.
  Article CAS Google Scholar
• Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999; 285: 727–729.
  Article CAS Google Scholar
• Cerwenka A, Baron JL, Lanier LL . Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc Natl Acad Sci USA 2001; 98: 11521–11526.
  Article CAS Google Scholar
• Diefenbach A, Jensen ER, Jamieson AM, Raulet DH . Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 2001; 413: 165–171.
  Article CAS Google Scholar
• Zhang J, Xu Z, Zhou X, Zhang H, Yang N, Wu Y et al. Loss of expression of MHC class I-related chain A (MICA) is a frequent event and predicts poor survival in patients with hepatocellular carcinoma. Int J Clin Exp Pathol 2014; 7: 3123–3231.
  PubMed PubMed Central Google Scholar
• Chitadze G, Lettau M, Bhat J, Wesch D, Steinle A, Fürst D et al. Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the “a disintegrin and metalloproteases” 10 and 17. Int J Cancer 2013; 133: 1557–1566.
  Article CAS Google Scholar
• Kaiser BK, Yim D, Chow IT, Gonzalez S, Dai Z, Mann HH et al. Disulphide-isomerase-enabled shedding of tumor-associated NKG2D ligands. Nature 2007; 447: 482–486.
  Article CAS Google Scholar
• Chitadze G, Bhat J, Lettau M, Janssen O, Kabelitz D . Generation of soluble NKG2D ligands: proteolytic cleavage, exosome secretion and functional implications. Scand J Immunol 2013; 78: 120–129.
  Article CAS Google Scholar
• Dai Z, Turtle CJ, Booth GC, Riddell SR, Gooley TA, Stevens AM et al. Normally occurring NKG2D+CD4+ T cells are immunosuppressive and inversely correlated with disease activity in juvenile-onset lupus. J Exp Med 2009; 206: 793–805.
  Article CAS Google Scholar
• Groh V, Smythe K, Dai Z, Spies T . Fas-ligand-mediated paracrine T cell regulation by the receptor NKG2D in tumor immunity. Nat Immunol 2006; 7: 755–762.
  Article CAS Google Scholar
• Zhang C, Zhang J, Niu J, Zhang J, Tian Z . Interleukin-15 improves cytotoxicity of natural killer cells via up-regulating NKG2D and cytotoxic effector molecule expression as well as STAT1 and ERK1/2 phosphorylation. Cytokine 2008; 42: 128–136.
  Article CAS Google Scholar
• Soriani A, Zingoni A, Cerboni C, Iannitto ML, Ricciardi MR, Di Gialleonardo V et al. ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. Blood 2009; 113: 3503–3511.
  Article CAS Google Scholar
• Diermayr S, Himmelreich H, Durovic B, Mathys-Schneeberger A, Siegler U, Langenkamp U et al. NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities. Blood 2008; 111: 1428–1436.
  Article CAS Google Scholar
• Bouchaud G, Gehrke S, Krieg C, Kolios A, Hafner J, Navarini AA et al. Epidermal IL-15Rα acts as an endogenous antagonist of psoriasiform inflammation in mouse and man. J Exp Med 2013; 210: 2105–2117.
  Article CAS Google Scholar
• Wendel M, Galani IE, Suri-Payer E, Cerwenka A . Natural killer cell accumulation in tumors is dependent on IFN-gamma and CXCR3 ligands. Cancer Res 2008; 68: 8437–8445.
  Article CAS Google Scholar
• González S, Groh V, Spies T . Immunobiology of human NKG2D and its ligands. Curr Top Microbiol Immunol 2006; 298: 121–138.
  PubMed Google Scholar
• Giri JG, Kumaki S Ahdieh M Friend DJ, Loomis A, Shanebeck K et al. Identification and cloning of a novel IL-15 binding protein that is structurally related to the alpha chain of the IL-2 receptor. EMBO J 1995; 14: 3654–3663.
  Article CAS Google Scholar
• Raulet DH, Gasser S, Gowen BG, Deng W, Jung H . Regulation of ligands for the NKG2D activating receptor. Annu Rev Immunol 2013; 31: 413–441.
  Article CAS Google Scholar